R.s. Surgipharm Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: R.s. Surgipharm Private Limited Pharmaceutical Export Portfolio Dataset — 7 Products, $431.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

R.s. Surgipharm Private Limited — Pharmaceutical Exporter Profile (2026) | 7 Products, $431.6K Trade | TransData Nexus

R.s. Surgipharm Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $431.6K Total Trade · DGFT Verified

R.s. Surgipharm Private Limited is an Indian pharmaceutical exporter with a total trade value of $431.6K across 7 products in 2 therapeutic categories. Based on 216 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Bevacizumab ($214.1K), Rituximab ($118.2K), Everolimus ($38.4K).

R.s. Surgipharm Private Limited — Export Portfolio & Destination Treemap

R.s. Surgipharm Private Limited pharmaceutical export portfolio — 7 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is R.s. Surgipharm Private Limited? — Company Overview & Market Position

R.S. Surgipharm Private Limited, established on April 2, 2013, is a private limited company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24230GJ2013PTC074294. Its authorized capital is ₹5.00 million, with a paid-up capital of ₹5.00 million. The registered office is located at 501/502 5th Floor, Serenity Square, Opp. Navrang Complex, Opp. Navrang School, Ahmedabad, Gujarat, 380009.

R.S. Surgipharm specializes in the distribution and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated in two therapeutic categories: Advanced Oncology (91.1%) and Immunosuppressants (8.9%). The top five exported products are Bevacizumab, Rituximab, Everolimus, Cabazitaxel, and Carfilzomib, collectively accounting for 94.7% of the total export value.

What Does R.s. Surgipharm Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Bevacizumab$214.1K 2

Product Portfolio — Top 7 by Export Value

R.s. Surgipharm Private Limited exports 7 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Bevacizumab	Advanced Oncology	$214.1K	71	0.5%	12
2	Rituximab	Advanced Oncology	$118.2K	63	0.6%	9
3	Everolimus	Immunosuppressants	$38.4K	35	0.1%	8
4	Cabazitaxel	Advanced Oncology	$23.0K	21	0.2%	10
5	Carfilzomib	Advanced Oncology	$15.2K	8	0.6%	10
6	Regorafenib	Advanced Oncology	$12.5K	11	1.2%	3
7	Topotecan	Advanced Oncology	$10.2K	7	0.3%	5

R.s. Surgipharm Private Limited exports 7 pharmaceutical products across 2 therapeutic categories with a total export value of $431.6K. The top category is Advanced Oncology (91.1% of portfolio), followed by Immunosuppressants (8.9%), indicating a concentrated portfolio with the top 5 products accounting for 94.7% of total export value.

R.s. Surgipharm Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding R.S. Surgipharm's manufacturing facilities are not publicly disclosed. The company focuses on the distribution and export of finished pharmaceutical formulations, suggesting that manufacturing may be outsourced to third-party contract manufacturers. This approach is common in the pharmaceutical industry, allowing companies to leverage specialized manufacturing capabilities while concentrating on distribution and market expansion.

3Key Leadership

The leadership team at R.S. Surgipharm includes:

Ashish Kantilal Shah: Director since April 2, 2013.
Jasmina Ashish Shah: Director since April 2, 2013.
Rajendrabhai Jivanlal Shah: Director since April 2, 2013.
Krunal Ashwinbhai Patel: Director since March 8, 2022.
Daksh Shah: Whole-Time Director since June 14, 2021.
Dushyantbhai Shashikantbhai Zaveri: Director since March 8, 2022.

These individuals bring a wealth of experience and leadership to the company, contributing to its growth and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does R.s. Surgipharm Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

R.S. Surgipharm's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in partnerships to distribute specific products, such as collaborating with Natco Pharma to offer Risdiplam (Natsmart) for the treatment of Spinal Muscular Atrophy (SMA). This partnership highlights the company's commitment to providing access to critical medications in regulated markets.

2Emerging Markets

R.S. Surgipharm has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on distributing high-quality pharmaceutical products positions it well to meet the growing healthcare needs in these regions. While specific details about WHO prequalification are not publicly available, the company's adherence to international quality standards suggests a commitment to meeting the regulatory requirements necessary for market access in these regions.

3Geographic Strategy

R.S. Surgipharm's export strategy is characterized by a focus on high-value oncology and immunosuppressant products, which constitute the majority of its export portfolio. This concentration indicates a strategic emphasis on specialized therapeutic areas with significant global demand. The company's expansion into emerging markets reflects a diversification strategy aimed at mitigating risks associated with overreliance on a single market and capitalizing on growth opportunities in developing regions.

R.s. Surgipharm Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding R.S. Surgipharm's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's focus on finished pharmaceutical formulations suggests that it may collaborate with contract manufacturers who hold the necessary FDA approvals for the production of these products. This approach allows R.S. Surgipharm to offer FDA-compliant products without directly engaging in manufacturing activities.

2WHO & EU GMP

While specific details about R.S. Surgipharm's WHO prequalification and EU Good Manufacturing Practice (GMP) certifications are not publicly disclosed, the company's commitment to quality is evident through its partnerships and product offerings. For instance, the collaboration with Natco Pharma to distribute Risdiplam (Natsmart) for SMA treatment indicates adherence to high-quality standards. The company's focus on distributing finished pharmaceutical formulations suggests that it ensures its products meet international quality standards, which is essential for market access in regulated regions.

3CDSCO & Indian Regulatory

R.s. Surgipharm Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

R.S. Surgipharm operates in a competitive landscape with several key players in the pharmaceutical distribution sector. While specific market share data is not publicly available, the company's focus on high-value oncology and immunosuppressant products positions it in direct competition with other specialized pharmaceutical distributors. The company's strategic partnerships, such as the collaboration with Natco Pharma for the distribution of Risdiplam (Natsmart), enhance its competitive edge by offering access to critical medications at affordable prices.

2Key Differentiators

R.S. Surgipharm's key differentiators include its specialized focus on oncology and immunosuppressant products, strategic partnerships with established pharmaceutical companies, and a commitment to providing access to essential medications in emerging markets. The company's adherence to international quality standards and regulatory compliance further distinguishes it in the competitive pharmaceutical distribution sector.

3Strategic Position

R.S. Surgipharm's current strategic direction emphasizes the distribution of high-value pharmaceutical products, particularly in the oncology and immunosuppressant therapeutic areas. The company's expansion into emerging markets reflects a proactive approach to diversifying its market presence and mitigating risks associated with overreliance on a single market. Looking ahead, R.S. Surgipharm is well-positioned to leverage its specialized product portfolio and strategic partnerships to drive growth and enhance its presence in both established and emerging markets.

Buyer Due Diligence Brief — Evaluating R.s. Surgipharm Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

R.S. Surgipharm's track record in the pharmaceutical distribution sector is characterized by a focus on high-quality products and strategic partnerships. The company's export volume and consistency are supported by its specialized product offerings and adherence to international quality standards. Reliability indicators include the absence of publicly available regulatory actions and the company's commitment to providing access to essential medications in emerging markets.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the manufacturing facilities hold FDA approvals for the production of pharmaceutical products.
WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice standards.
EU GMP Certification: Verify that the manufacturing facilities adhere to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — R.s. Surgipharm Private Limited

How many pharmaceutical products does R.s. Surgipharm Private Limited export from India?

R.s. Surgipharm Private Limited exports 7 pharmaceutical products across 2 therapeutic categories. The top exports are Bevacizumab ($214.1K), Rituximab ($118.2K), Everolimus ($38.4K), Cabazitaxel ($23.0K), Carfilzomib ($15.2K). Total export value is $431.6K.

What is R.s. Surgipharm Private Limited's total pharmaceutical export value?

R.s. Surgipharm Private Limited's total pharmaceutical export value is $431.6K, based on 216 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does R.s. Surgipharm Private Limited cover?

R.s. Surgipharm Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (91.1%, 6 products), Immunosuppressants (8.9%, 1 products).

Get Full R.s. Surgipharm Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.